Kexing Holdings (Hong Kong) includes Beijing Kexing Holding Biotechnology Co., Ltd. and Beijing Kexing Zhongwei Biotechnology Co., Ltd. Weiming Pharmaceutical is the second largest shareholder of Kexing Holding Biotechnology Co., Ltd. ..
The company was incorporated in Peking University Biological City, Zhongguancun High-tech Park, Beijing on 200 1.
Kexing Holdings not only owns Kexing Zhongwei, but also owns Beijing Kexing Biological Products Co., Ltd. (hereinafter referred to as "Beijing Kexing"), Kexing (Dalian) Vaccine Technology Co., Ltd. (hereinafter referred to as "Dalian Kexing") and Beijing Kexing Zhong Yi Biomedical Co., Ltd. (hereinafter referred to as "Kexing Zhong Yi") through wholly-owned subsidiaries.
Among them, Beijing Kexing has the highest reputation and the strongest strength. According to media reports, the first phase I clinical study of inactivated SARS virus vaccine has been completed, and the first inactivated hepatitis A vaccine, the first combined hepatitis A vaccine and the first H 1N 1 influenza A vaccine in the world have been developed. It is the only China vaccine company listed in North America.
Beijing Kexing Biological is the first vaccine company listed in the United States in China, holding 765,438+0.6% shares in Beijing Kexing Biological Products Co., Ltd. through its Hong Kong branch. Beijing Kexing Holding Company also has a wholly-owned subsidiary in Tangshan, Hebei Province-Tangshan Yi 'an Bioengineering Co., Ltd., which is dedicated to the research and development of veterinary vaccines.
The main business scope of the enterprise includes scientific research, development and design of biological vaccine technology, diagnostic reagents and technologies, provision of technical consultation, technical services and technology transfer, commodity import and export trade, pharmaceutical manufacturing and tertiary medical machinery.
The purpose of the company's establishment and operation: in line with the desire to develop China's bioengineering high-tech industry, we will adopt advanced scientific and technological achievements at home and abroad and introduce international scientific management methods to conduct research, production and sales of human vaccines and related products, and provide technical consultation and technical services to improve the prevention and treatment level of various major diseases at home and abroad, including hepatitis A and hepatitis B, and make contributions to human health.